About the Authors
- Susanne Blöß
-
Affiliation Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Hannover, Germany
- Christian Klemann
-
Affiliations Center for Chronic Immunodeficiency (CCI), University Medical Center Freiburg, University of Freiburg, Freiburg, Germany, Center for Pediatric and Adolescent Medicine, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany
- Ann-Katrin Rother
-
Affiliation Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Hannover, Germany
- Sandra Mehmecke
-
Affiliations Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Hannover, Germany, Department of Neurology, Hannover Medical School, Hannover, Germany
- Ulrike Schumacher
-
Affiliation DRK Clementinenkrankenhaus, Hannover, Germany
- Urs Mücke
-
Affiliation Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Hannover, Germany
- Martin Mücke
-
Affiliation Center for Rare Diseases Bonn (ZSEB), University Hospital of Bonn, Bonn, Germany
- Christiane Stieber
-
Affiliation Center for Rare Diseases Bonn (ZSEB), University Hospital of Bonn, Bonn, Germany
- Frank Klawonn
-
Affiliations Ostfalia University of Applied Sciences, Wolfenbuettel, Germany, Helmholtz Centre for Infection Research, Braunschweig, Germany
- Xiaowei Kortum
-
Affiliation Ostfalia University of Applied Sciences, Wolfenbuettel, Germany
- Werner Lechner
-
Affiliation Improved Medical Diagnostics IMD GmbH, Hannover, Germany
- Lorenz Grigull
-
* E-mail: Grigull.lorenz@mh-hannover.de
Affiliation Department of Pediatric Hematology and Oncology, Hannover Medical School, Hannover, Hannover, Germany
Competing Interests
The commercial affiliation of FK, LG, and WL to Improved Medical Diagnostics, IMD GmbH, Germany, did not play a role in our study and this did not alter our adherence to all PLOS ONE policies on sharing data and materials.
Author Contributions
Conceptualization: LG SB US CK. Data curation: SB LG. Formal analysis: FK WL XK MM. Funding acquisition: LG. Investigation: SB LG CK AKR. Methodology: LG SB CK. Project administration: LG. Resources: WL FK. Software: WL XK FK. Supervision: LG. Validation: LG MM UM SM CS AKR. Visualization: CK. Writing – original draft: LG SB. Writing – review & editing: CK MM CS.